Widely Recognized and Experienced Leader in Global Food & Regulatory Industry Joins BioHarvest as Senior Consultant

Vancouver, BC / November 10, 2020 / BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) (CSE: BHSC) announces the appointment of Dr. Rhona Applebaum as its Senior Consultant for Regulatory and Environmental Affairs. Dr. Applebaum will assist the company in developing strategies for prompt and cost-effective regulatory approvals of VINIA®, the Company’s Red Grape Cell product, and other pipeline products in development across priority geographies and business verticals in order to meet the growing business and consumer demand for health and wellness products. Dr. Applebaum will assist the company in conducting a sustainability assessment of the Company’s Biofarming Technology versus conventional farming and other technologies. She will also assist the company in devising and executing a strategy to apply VINIA® to the pharma and medical food markets. In her role, she will report directly to Ilan Sobel, the CEO.

Dr. Rhona Applebaum, Ph.D., is a widely recognized and experienced leader at the nexus of industry, government and civil society, garnered from four decades of distinguished service in the food and regulatory sector. Rhona excels at building strong relationships across public and private sectors alike. Serving most recently as the Coca-Cola Company first Chief Science and Health Officer, Rhona developed and executed the Company’s global health and well-being strategy. Previously Rhona was executive VP and Chief Science Officer for the National Food Processors Association (NFPA).  Rhona has held numerous high-level public assignments, with service on the US Department of State’s Advisory Committee on International and Economic Policy, CDC Foundation’s Roundtable on Global Health Threats, the Harvard Medical School Global Health Advisory Council, Center for Strategic & International Studies Commission on Smart Global Health Policy and various Advisory Boards for the USFDA and USDA. She received her BA from Wilson College in history and biology, a Master’s degree in nutrition and food sciences from Drexel University, and a Ph.D. in food microbiology and food safety from the University of Wisconsin.

“As we are working towards our objective to make our products available to consumers in multiple markets and expose our technology to different verticals, we could not be happier than having Rhona on the team,” said Ilan Sobel and added “We are privileged to have a leader in regulatory science and policy of Rhona’s caliber joining us at BioHarvest. We will benefit from her expertise in the food and health sectors. Her deep understanding of the complex relationships between industry, science, regulatory policy, and the public good is going to assist the company in bringing the wealth of the Biofarming technology to consumers across the globe. She will do so while working on validating the superiority of the technology across many environmental aspects as well. Rhona’s contribution will also prove critical in our objective to expand our unique offerings to the pharma industry”. 

About BioHarvest Sciences Inc.

Based in Vancouver BC, BioHarvest Sciences Inc. is the developer and exclusive owner of the proprietary and patent-protected BioFarming technology. It is the first and only industrial-scale plant cell technology capable of producing the active plant ingredients without the necessity to grow the plant itself. The Company’s technology is non-GMO and has already been validated by VINIA®, the red grapes cells functional food/dietary supplement produced and sold by BioHarvest Sciences Inc. The Company plans to generate significant revenue within the global nutraceutical ingredients and dietary supplements market with VINIA® and other Super Fruit Nutraceutical products. Further, by adapting this technology to the Cannabis plant, and building adequate production capacity, BioHarvest Sciences Inc.’s objective is to become a leading supplier of Cannabis for both medicinal and legal recreational purposes. Visit: www.bioharvest.com.

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer

For further information, please contact:

Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com


Forward-Looking Statements 

Information set forth in this news release includes forward-looking statements that are based on management’s current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that strong sales metrics experienced to date will result in future demand or that proposed additional marketing expenditures will result in increased sales. Markets for nutraceuticals are unpredictable and subject to changes in consumer tastes and trends as well as economic factors beyond our control.  Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance, and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. There is no assurance that the Company sales revenue for 2022 will reach USD 5 to 7 million and there is no assurance that the Company cash flow breaking point will be achieved in 2023. There is no assurance of commercial availability of our Cannabis product in 2022 or that the Company achieves the conversion of the two tons VINIA® facility to Cannabis production in 2022. These things are subject to construction and approval delays and uncertainties that may be beyond the control of BioHarvest. Projected sales of Cannabis will require the Company to obtain production and/or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures. 

Readers are cautioned that revenue alone do not give an accurate picture of the financial position of the Company and should be read in the context of the Company’s annual and quarterly financial statements.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.